Akcea Therapeutics
E561116
Akcea Therapeutics is a biopharmaceutical company focused on developing RNA-targeted therapies for rare and serious diseases, particularly in the cardiometabolic and hereditary amyloidosis space.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Akcea Therapeutics canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T6005141 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Akcea Therapeutics Context triple: [Tegsedi, coDevelopedBy, Akcea Therapeutics]
-
A.
Alkermes
Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
-
B.
AbbVie
AbbVie is a global biopharmaceutical company known for developing and marketing innovative therapies in areas such as immunology, oncology, and neuroscience.
-
C.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
D.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company best known for developing transformative therapies for cystic fibrosis and other serious diseases using a precision medicine approach.
-
E.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Akcea Therapeutics Target entity description: Akcea Therapeutics is a biopharmaceutical company focused on developing RNA-targeted therapies for rare and serious diseases, particularly in the cardiometabolic and hereditary amyloidosis space.
-
A.
Alkermes
Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
-
B.
AbbVie
AbbVie is a global biopharmaceutical company known for developing and marketing innovative therapies in areas such as immunology, oncology, and neuroscience.
-
C.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
D.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company best known for developing transformative therapies for cystic fibrosis and other serious diseases using a precision medicine approach.
-
E.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
- F. None of above. chosen
Statements (31)
| Predicate | Object |
|---|---|
| instanceOf | biopharmaceutical company ⓘ |
| businessModel | development and commercialization of RNA therapeutics ⓘ |
| collaboratesWith | Ionis Pharmaceuticals ⓘ |
| country |
United States
ⓘ
linked to:
United States of America
|
| focus |
RNA-targeted therapies
ⓘ
cardiometabolic diseases ⓘ hereditary amyloidosis ⓘ rare diseases ⓘ serious diseases ⓘ |
| formerStockExchangeListing | NASDAQ ⓘ |
| foundedBy | Ionis Pharmaceuticals ⓘ |
| hasPipeline |
RNA-targeted drugs for amyloidosis
ⓘ
RNA-targeted drugs for cardiometabolic risk reduction ⓘ RNA-targeted drugs for lipid disorders ⓘ |
| headquartersLocation |
Boston, Massachusetts
ⓘ
United States ⓘ
linked to:
United States of America
|
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| parentCompany | Ionis Pharmaceuticals ⓘ |
| product |
Tegsedi
ⓘ
Waylivra ⓘ |
| regulatoryApproval |
Tegsedi approval for hereditary transthyretin-mediated amyloidosis
ⓘ
Waylivra approval for familial chylomicronemia syndrome ⓘ |
| specialization |
hereditary transthyretin-mediated amyloidosis
ⓘ
rare lipid disorders ⓘ |
| technologyPlatform | RNA-targeted antisense technology ⓘ |
| therapeuticArea |
cardiovascular diseases
ⓘ
metabolic diseases ⓘ neurologic manifestations of amyloidosis ⓘ |
| therapyType | antisense oligonucleotide therapies ⓘ |
| tickerSymbol | AKCA ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Akcea Therapeutics Description of subject: Akcea Therapeutics is a biopharmaceutical company focused on developing RNA-targeted therapies for rare and serious diseases, particularly in the cardiometabolic and hereditary amyloidosis space.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.